Mi az ára Psyence Biomedical Ltd. (PBM)

Psyence Biomedical Ltd. (PBM) ára $3.20

Mi a Psyence Biomedical Ltd. (PBM piaci tőkésítése)

Psyence Biomedical Ltd. piaci tőkésítése (PBM) $60.86K

Psyence Biomedical Ltd. (PBM) Ár és Piaci Kapitalizáció

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

A PBM ára	B aktíva	A B piaci tőkésítése	Eredmények
$286,146,304 $60.86K	NVDA	$5.442T	+8,942,071,889.08%
$234,674,132 $60.86K	AAPL	$4.463T	+7,333,566,533.19%
$219,574,394 $60.86K	GOOG	$4.176T	+6,861,699,701.45%
$193,466,829 $60.86K	MSFT	$3.680T	+6,045,838,302.43%
$150,853,351 $60.86K	AMZN	$2.869T	+4,714,167,126.04%

A PBM ára

B aktíva

A B piaci tőkésítése

Eredmények

$286,146,304 $60.86K